Business

Inhaled drug developer Prosonix has announced a global licensing agreement with Mylan for its generic versions of GSK’s Flixotide and Flovent fluticasone propionate MDIs for the treatment of asthma. The deal covers two Prosonix MDIs,… Read more . . .

According to Hovione, the United States Patent and Trademark Office (USPTO) has granted the company a patent for its XCAPs capsule-based dry powder inhaler. The European Patent Office granted the company a patent for the… Read more . . .

Swedish pharmaceutical company Meda has confirmed that Mylan approached the company with a takeover offer and that Meda rejected the offer. According to Meda, “All continued discussions between Meda and Mylan have been terminated without… Read more . . .

Swedish CDMO Recipharm, which has a dedicated DPI manufacturing facility in the UK, has begun trading on the Stockholm stock exchange, according to NASDAQ OMX. Recipharm had announced the IPO in March 2014. Recipharm CEO… Read more . . .

Skyepharma revenues were up 25% in 2013, the company said, in large part due to increased sales of its Flutiform fluticasone/formoterol MDI. The company also announced that it will seek to raise £112 million through… Read more . . .

NanoBio has announced that Merck has acquired exclusive rights to NanoBio’s NanoStat nanoemulsion adjuvant for an intranasal respiratory syncytial virus (RSV) vaccine. Merck also acquired non-exclusive rights to the adjuvant for use in an intranasal… Read more . . .

Non-profit R&D organization Southwest Research Institute (SwRI) has announced that it has received a 28-month contract extension worth $8.3 million from the US Department of Health and Human Services Biomedical Advanced Research and Development Authority… Read more . . .

Vectura has announced that under a license agreement with “the US division of a leading international pharmaceutical company” signed in 2011, it has reached a milestone associated with the US development of its VR315 salmeterol/fluticasone… Read more . . .

According to a report in the Wall Street Journal, a court in Cologne, Germany has issued a preliminary injunction preventing Sandoz from marketing its AirFluSal Forspiro in Germany. GlaxoSmithKline had argued that Sandoz’s salmeterol/fluticasone DPI… Read more . . .